دورية أكاديمية
أعرض في EDS

Evaluation and deployment of isotype-specific salivary antibody assays for detecting previous SARS-CoV-2 infection in children and adults.

التفاصيل البيبلوغرافية
العنوان: Evaluation and deployment of isotype-specific salivary antibody assays for detecting previous SARS-CoV-2 infection in children and adults.
المؤلفون: Thomas AC; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. amyc.thomas@bristol.ac.uk.; Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK. amyc.thomas@bristol.ac.uk., Oliver E; Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK., Baum HE; Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK., Gupta K; School of Biochemistry, University of Bristol, Bristol, UK.; BrisSynBio, University of Bristol, Bristol, UK.; Imophoron Ltd, Science Creates, Old Market, Midland Road, Bristol, UK., Shelley KL; School of Biochemistry, University of Bristol, Bristol, UK.; BrisSynBio, University of Bristol, Bristol, UK.; School of Chemistry, University of Bristol, Bristol, UK., Long AE; Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK., Jones HE; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK., Smith J; Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK., Hitchings B; Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK., di Bartolo N; School of Biochemistry, University of Bristol, Bristol, UK.; NIHR Blood and Transplant Research Unit in Red Cell Products, University of Bristol, Bristol, UK., Vasileiou K; School of Biochemistry, University of Bristol, Bristol, UK., Rabi F; School of Biochemistry, University of Bristol, Bristol, UK., Alamir H; Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK., Eghleilib M; Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK., Francis O; Bristol Veterinary School, University of Bristol, Bristol, UK., Oliver J; Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK., Morales-Aza B; Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK., Obst U; School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK., Shattock D; Bristol Bioresource Laboratories, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK., Barr R; Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.; Bristol Royal Hospital for Children, University Hospitals Bristol and Weston NHS Foundation Trust, Upper Maudlin Street, Bristol, BS2 8BJ, UK., Collingwood L; Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK., Duale K; Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK., Grace N; Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK., Livera GG; Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK., Bishop L; Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK., Downing H; NIHR Bristol Biomedical Research Centre, University of Bristol, Bristol, UK., Rodrigues F; Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.; Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal., Timpson N; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.; MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, Bristol, UK., Relton CL; MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, Bristol, UK., Toye A; School of Biochemistry, University of Bristol, Bristol, UK.; NIHR Blood and Transplant Research Unit in Red Cell Products, University of Bristol, Bristol, UK., Woolfson DN; School of Biochemistry, University of Bristol, Bristol, UK.; BrisSynBio, University of Bristol, Bristol, UK.; School of Chemistry, University of Bristol, Bristol, UK., Berger I; Max Planck Bristol Centre for Minimal Biology, University of Bristol, Bristol, UK., Goenka A; Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.; Paediatric Immunology & Infectious Diseases, Bristol Royal Hospital for Children, Bristol, UK., Davidson AD; School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK., Gillespie KM; Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK., Williams AJK; Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK., Bailey M; Bristol Veterinary School, University of Bristol, Bristol, UK., Brooks-Pollock E; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK., Finn A; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.; Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.; Paediatric Immunology & Infectious Diseases, Bristol Royal Hospital for Children, Bristol, UK., Halliday A; Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
مؤلفون مشاركون: CoMMinS Study Team
المصدر: Communications medicine [Commun Med (Lond)] 2023 Mar 15; Vol. 3 (1), pp. 37. Date of Electronic Publication: 2023 Mar 15.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Portfolio Country of Publication: England NLM ID: 9918250414506676 Publication Model: Electronic Cited Medium: Internet ISSN: 2730-664X (Electronic) Linking ISSN: 2730664X NLM ISO Abbreviation: Commun Med (Lond) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [London] : Nature Portfolio, [2021]-
مستخلص: Background: Saliva is easily obtainable non-invasively and potentially suitable for detecting both current and previous SARS-CoV-2 infection, but there is limited evidence on the utility of salivary antibody testing for community surveillance.
Methods: We established 6 ELISAs detecting IgA and IgG antibodies to whole SARS-CoV-2 spike protein, to its receptor binding domain region and to nucleocapsid protein in saliva. We evaluated diagnostic performance, and using paired saliva and serum samples, correlated mucosal and systemic antibody responses. The best-performing assays were field-tested in 20 household outbreaks.
Results: We demonstrate in test accuracy (N = 320), spike IgG (ROC AUC: 95.0%, 92.8-97.3%) and spike IgA (ROC AUC: 89.9%, 86.5-93.2%) assays to discriminate best between pre-pandemic and post COVID-19 saliva samples. Specificity was 100% in younger age groups (0-19 years) for spike IgA and IgG. However, sensitivity was low for the best-performing assay (spike IgG: 50.6%, 39.8-61.4%). Using machine learning, diagnostic performance was improved when a combination of tests was used. As expected, salivary IgA was poorly correlated with serum, indicating an oral mucosal response whereas salivary IgG responses were predictive of those in serum. When deployed to household outbreaks, antibody responses were heterogeneous but remained a reliable indicator of recent infection. Intriguingly, unvaccinated children without confirmed infection showed evidence of exposure almost exclusively through specific IgA responses.
Conclusions: Through robust standardisation, evaluation and field-testing, this work provides a platform for further studies investigating SARS-CoV-2 transmission and mucosal immunity with the potential for expanding salivo-surveillance to other respiratory infections in hard-to-reach settings.
(© 2023. The Author(s).)
References: J Hyg (Lond). 1985 Aug;95(1):173-89. (PMID: 2991366)
Euro Surveill. 2020 Jan;25(3):. (PMID: 31992387)
Nat Med. 2020 Jul;26(7):1033-1036. (PMID: 32398876)
J Allergy Clin Immunol. 2021 Feb;147(2):545-557.e9. (PMID: 33221383)
Nature. 2020 Aug;584(7820):274-278. (PMID: 32760003)
Microbiol Spectr. 2021 Oct 31;9(2):e0073121. (PMID: 34523985)
Lancet Infect Dis. 2020 Dec;20(12):1390-1400. (PMID: 32979318)
Sci Transl Med. 2021 Jan 20;13(577):. (PMID: 33288662)
Mucosal Immunol. 2016 Jul;9(4):884-93. (PMID: 26509875)
Lancet. 2021 Apr 10;397(10282):1347-1348. (PMID: 33770519)
Lancet Microbe. 2021 Feb;2(2):e60-e69. (PMID: 33521709)
Vaccine. 2021 Jul 22;39(32):4423-4428. (PMID: 34210573)
Nat Commun. 2021 Oct 27;12(1):6197. (PMID: 34707161)
Viruses. 2022 Jul 08;14(7):. (PMID: 35891471)
Cell Rep Med. 2021 Jul 20;2(7):100327. (PMID: 34124701)
Sci Transl Med. 2021 Jan 20;13(577):. (PMID: 33288661)
Science. 2020 Nov 6;370(6517):725-730. (PMID: 32958580)
Nucleic Acids Res. 2012 Aug;40(15):e115. (PMID: 22730293)
Nature. 2020 Aug;584(7819):115-119. (PMID: 32454513)
JAMA Netw Open. 2022 Mar 1;5(3):e221313. (PMID: 35262717)
J Infect. 2021 Jul;83(1):104-111. (PMID: 33933527)
Front Immunol. 2020 Nov 30;11:611337. (PMID: 33329607)
Nat Commun. 2021 Sep 23;12(1):5621. (PMID: 34556667)
BMJ. 2020 Nov 11;371:m4262. (PMID: 33177070)
Nat Med. 2021 Jul;27(7):1205-1211. (PMID: 34002089)
Nat Med. 2022 Nov;28(11):2416-2423. (PMID: 36302894)
EBioMedicine. 2021 Jun;68:103414. (PMID: 34098341)
J Clin Microbiol. 2020 Dec 17;59(1):. (PMID: 33067270)
Front Immunol. 2022 Nov 09;13:968317. (PMID: 36439154)
Infect Immun. 1981 Sep;33(3):697-703. (PMID: 7287178)
mBio. 2021 Oct 26;12(5):e0190821. (PMID: 34544278)
Sci Immunol. 2020 Oct 8;5(52):. (PMID: 33033173)
Ann N Y Acad Sci. 2007 Mar;1098:288-311. (PMID: 17435136)
Cell. 2021 Apr 1;184(7):1858-1864.e10. (PMID: 33631096)
Mucosal Immunol. 2020 Jan;13(1):12-21. (PMID: 31740744)
J Immunol. 2022 Mar 15;208(6):1500-1508. (PMID: 35228262)
Microbiol Spectr. 2022 Feb 23;10(1):e0151221. (PMID: 35171028)
Biometrics. 1988 Sep;44(3):837-45. (PMID: 3203132)
J Oral Microbiol. 2013;5:. (PMID: 23487566)
Nat Commun. 2021 May 25;12(1):3109. (PMID: 34035301)
معلومات مُعتمدة: MR/V028545/1 RCUK | Medical Research Council (MRC); MR/V038613/1 RCUK | Medical Research Council (MRC); MC/PC/19067 RCUK | Medical Research Council (MRC); 217509/Z/19/Z Wellcome Trust (Wellcome); 202802/Z/16/Z Wellcome Trust (Wellcome)
فهرسة مساهمة: Investigator: H Alamir; HE Baum; A Goenka; A Halliday; B Hitchings; E Oliver; D Shattock; J Smith; AC Thomas; D Adegbite; R Antico; J Atkins; E Baxter; L Bishop; A Boon; E Bridgeman; L Collingwood; C Derrick; L Fleming; RG Garcia; GG Liveria; N Grace; L Grimwood; J Kinney; R Myrtou; A O'Rouke; J Oliver; C Payne; R Pennie; M Powell; LR Garcia; A Storer-Martin; J Summerhill; A Taylor; Z Taylor; H Thompson; S Thomson-Hill; L Underwood; G Valentine; S Vergnano; A Way; M White; A Williams; D Allen; J Anderson; M Ardeshir; M Booth; C Butler; M Chaulagain; A Darling; N Dayrell-Armes; K Duale; M Eghleilib; C Farren; D Freestone; J Harkness; W Healy; MJ Flanagan; M Khalique; N King; A Koi; M Lyall; B Morales-Aza; M Pozo; AR Pereira; J Rosa; L Setter; L Thomas; D Thomas; J Vowles
Local Abstract: [plain-language-summary] If a person has been previously infected with SARS-CoV-2 they will produce specific proteins, called antibodies. These are present in the saliva and blood. Saliva is easier to obtain than blood, so we developed and evaluated six tests that detect SARS-CoV-2 antibodies in saliva in children and adults. Some tests detected antibodies to a particular protein made by SARS-CoV-2 called the spike protein, and these tests worked best. The most accurate results were obtained by using a combination of tests. Similar tests could also be developed to detect other respiratory infections which will enable easier identification of infected individuals.
تواريخ الأحداث: Date Created: 20230316 Latest Revision: 20230318
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10016188
DOI: 10.1038/s43856-023-00264-2
PMID: 36922542
قاعدة البيانات: MEDLINE
الوصف
تدمد:2730-664X
DOI:10.1038/s43856-023-00264-2